Industry
Biotechnology
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 20, 2024 | 11:04 am
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 8:24 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 12:24 pm
Portfolio Pulse from Benzinga Newsdesk
June 24, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 8:19 pm
Portfolio Pulse from Benzinga Newsdesk
February 14, 2024 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 9:15 pm
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 9:13 pm
Portfolio Pulse from Avi Kapoor
December 13, 2023 | 12:55 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.